Discovery and Optimization of a Series of Novel Morpholine-Containing USP1 Inhibitors
Journal of Medicinal Chemistry · 2025
DOI: 10.1021/acs.jmedchem.4c02792 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2025. Verfasst von Junjie Zhang und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicinal Chemistry, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai 201203, P. R. Chi…. Hauptthemen laut MEDLINE: Antineoplastic Agents, Morpholines. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Strategic Priority Research Program of the Chinese Academy of Sciences.
Abstract (Originalsprache)
Ubiquitin-specific protease 1 (USP1), a well-known member of the deubiquitinating enzymes, serves as a key regulator in DNA damage repair (DDR) processes. Herein, we utilized ring-opening and cyclization strategies based on KSQ-4279 to design a novel series of USP1 inhibitors featuring a morpholine scaffold. Notably, compound 38-P2 exhibited a more potent enzymatic and cellular inhibition activity compared to KSQ-4279. Mechanistically, 38-P2 was characterized as a selective, reversible, and noncompetitive USP1 inhibitor. 38-P2 efficiently activated the DDR pathway, induced cell cycle arrest and cell apoptosis, and inhibited cell survival. Importantly, it enhanced the sensitivity of olaparib-resistant cells to olaparib and showed a synergetic effect with andrographolide in BRCA-proficient cancer cells. Furthermore, 38-P2 had favorable pharmacokinetic profiles and good safety properties in vitro and in vivo. In the MDA-MB-436 xenograft model, 38-P2 displayed significant, dose-dependent antitumor efficacy. Overall, these findings indicate that 38-P2 is a promising lead compound for further drug development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medicinal Chemistry, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai 201203, P. R. China.
- State Key Laboratory of Chemical Biology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, P. R. China.
- University of Chinese Academy of Sciences, No. 19A Yuquan Road, Beijing 100049, P. R. China.
- State Key Laboratory of Drug Research, Cancer Research Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
- School of Pharmacy, Jiangxi Medical College, Nanchang University, Nanchang, China.
- School of Pharmacy, Shanxi Medical University, Taiyuan 030001, China.
ORCID-Profile: Bing Xiong, Tongchao Liu
Förderung
- National Natural Science Foundation of China
- Strategic Priority Research Program of the Chinese Academy of Sciences
Zitieren
APA
Zhang, J., Liu, B., Ren, R., Song, S., Bao, X., Huan, X., Li, H., Xu, J., Yu, T., Wang, R., Miao, Z. H., Xiong, B., He, J., & Liu, T. (2025). Discovery and Optimization of a Series of Novel Morpholine-Containing USP1 Inhibitors. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c02792
Vancouver
Zhang J, Liu B, Ren R, Song S, Bao X, Huan X, et al. Discovery and Optimization of a Series of Novel Morpholine-Containing USP1 Inhibitors. Journal of Medicinal Chemistry. 2025. doi:10.1021/acs.jmedchem.4c02792
BibTeX
@article{Zhang2025,
author = {Zhang, Junjie and Liu, Benjin and Ren, Ruyue and Song, Shanshan and Bao, Xubin and Huan, Xiajuan and Li, Hongrui and Xu, Jiahao and Yu, Ting and Wang, Ruifeng and Miao, Ze-Hong and Xiong, Bing and He, Jinxue and Liu, Tongchao},
title = {Discovery and Optimization of a Series of Novel Morpholine-Containing USP1 Inhibitors},
journal = {Journal of Medicinal Chemistry},
year = {2025},
doi = {10.1021/acs.jmedchem.4c02792}
}
EUVIMED